Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Abstract
Patients with inflammatory bowel disease (IBD) have an increased risk of colon cancer. However, the immune cells and cytokines that mediate the transition from intestinal inflammation to cancer are poorly understood. We show that bacteria-induced colon cancer is accompanied by differential accumulation of IL-17(+)IL-22(+) colonic innate lymphoid cells (cILCs), which are phenotypically distinct from LTi and NK-22 cells, and that their depletion in mice with dysplastic inflammation blocks the development of invasive colon cancer. Analysis of the functional role of distinct Type 17 cytokines shows that although blockade of IL-17 inhibits some parameters of intestinal inflammation, reduction in dysplasia and colorectal cancer (CRC) requires neutralization of IL-22 indicating a unique role for IL-22 in the maintenance of cancer in this model. Mechanistic analyses showed that IL-22 selectively acts on epithelial cells to induce Stat3 phosphorylation and proliferation. Importantly, we could detect IL-22(+)CD3(+) and IL-22(+)CD3(−) cells in human CRC. Our results describe a new activity of IL-22 in the colon as a nonredundant mediator of the inflammatory cascade required for perpetuation of CRC, highlighting the IL-22 axis as a novel therapeutic target in colon cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although known to exert a tumor-promoting effect in colorectal cancer (Kirchberger et al., 2013; Wang et al., 2017)”
From Commensal Microbiota Promote Lung Cancer Development via γδ T Cells (2019) · cites this paper as Kirchberger et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039 · cited 1×
“…in many mouse models (Hue et al., 2006; Izcue et al., 2008), and its components IL-23R and Stat3 are not only associated with IBD susceptibility (Duerr et al., 2006; Barrett et al., 2008) but also involved in inflammation-associated cancer in the skin and colon (Langowski et al., 2006; Bollrath…”
BackgroundThe risk of colorectal cancer in ulcerative colitis: a meta-analysis
Eaden, J. A., Abrams, K. R., & Mayberry, J. F. (2001) · Gut · doi:10.1136/gut.48.4.526 · Cited by 2,959 · cited 1×
“In inflammatory bowel disease (IBD) patients, deranged inflammatory responses toward the intestinal microbiota increase the risk of colon cancer twofold (Eaden et al., 2001).”
BackgroundGenome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
the NIDDK IBD Genetics Consortium, Barrett, J. C., the Belgian-French IBD Consortium, the Wellcome Trust Case Control Consortium, Hansoul, S., Nicolae, D. L., Cho, J. H., Duerr, R. H., Rioux, J. D., Brant, S. R., et al. (2008) · Nature Genetics · doi:10.1038/ng.175 · Cited by 2,593 · cited 1×
“…(Hue et al., 2006; Izcue et al., 2008), and its components IL-23R and Stat3 are not only associated with IBD susceptibility (Duerr et al., 2006; Barrett et al., 2008) but also involved in inflammation-associated cancer in the skin and colon (Langowski et al., 2006; Bollrath et al., 2009;…”
BackgroundLiang, S. C., Tan, X.-Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., & Fouser, L. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061308 · Cited by 2,330 · cited 8×
“It is now appreciated that a Type 17 cytokine expression signature is not restricted to Th-17 cells, and that cytokines such as IL-17 and IL-22 can be produced by unconventional T cell populations and more recently described RORtexpressing innate lymphoid populations (Pearson et al., 2012).”
BackgroundInfluentialCrypt stem cells as the cells-of-origin of intestinal cancer
Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., Danenberg, E., Clarke, A. R., Sansom, O. J., & Clevers, H. (2009) · Nature · doi:10.1038/nature07602 · Cited by 2,166 · cited 1×
“IL-22 may also promote cancer through direct effects on intestinal epithelial stem cells, previously shown to be key precursors for intestinal cancer (Barker et al., 2009).”
BackgroundGrivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155 · cited 2×
“The role of Stat3 in colon cancer is well known but this has been attributed to activation by IL-6 and IL-11 (Ernst et al., 2008; Grivennikov et al., 2009).”
BackgroundFusobacterium nucleatum infection is prevalent in human colorectal carcinoma
Castellarin, M., Warren, R. L., Freeman, J. D., Dreolini, L., Krzywinski, M., Strauss, J., Barnes, R., Watson, P., Allen-Vercoe, E., Moore, R. A., et al. (2012) · Genome Research · doi:10.1101/gr.126516.111 · Cited by 2,043 · cited 1×
“Furthermore, certain species like the anaerobic Fusobacterium nucleatum were found to be associated with human CRC tissue (Castellarin et al., 2012; Kostic et al., 2012).”
BackgroundGenomic analysis identifies association of Fusobacterium with colorectal carcinoma
Kostic, A. D., Gevers, D., Pedamallu, C. S., Michaud, M., Duke, F., Earl, A. M., Ojesina, A. I., Jung, J., Bass, A. J., Tabernero, J., et al. (2012) · Genome Research · doi:10.1101/gr.126573.111 · Cited by 1,960 · cited 1×
“Furthermore, certain species like the anaerobic Fusobacterium nucleatum were found to be associated with human CRC tissue (Castellarin et al., 2012; Kostic et al., 2012).”
BackgroundInterleukin-22 mediates early host defense against attaching and effacing bacterial pathogens
Zheng, Y., Valdez, P. A., Danilenko, D. M., Hu, Y., Sa, S. M., Gong, Q., Abbas, A. R., Modrusan, Z., Ghilardi, N., de Sauvage, F. J., et al. (2008) · Nature Medicine · doi:10.1038/nm1720 · Cited by 1,921 · cited 8×
“IL-23 also drives colon cancer in an APC model, where it is induced in tumor-associated myeloid 928 Interleukin-22 in colon cancer | Kirchberger et al. (Reference numbers: 11/YH/0020 and 09/H0606/5) and informed written consent was given by all study patients.”
BackgroundInfluentialWu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812 · cited 3×
“Th17 cell infiltration was also found in animal models of colon cancer, such as the ApcMin model driven by the enterotoxigenic bacterium Bacteroides fragilis, where blockade of IL-17 decreased tumor incidence (Wu et al., 2009).”
Background
Cited by
Intestinal epithelial cells: regulators of barrier function and immune homeostasis
Peterson, L. W., & Artis, D. (2014) · Nature Reviews Immunology · doi:10.1038/nri3608 · Cited by 3,173
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
Innate Lymphoid Cells: 10 Years On
Vivier, E., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J. P., Eberl, G., Koyasu, S., Locksley, R. M., McKenzie, A. N. J., Mebius, R. E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.017 · Cited by 2,124
“, 2012), the proliferationpromoting effect of IL-22 on epithelial cells can also sustain the progression of colon cancer (Kirchberger et al., 2013; Hernandez et al., 2018).”
The biology of innate lymphoid cells
Artis, D., & Spits, H. (2015) · Nature · doi:10.1038/nature14189 · Cited by 1,634
IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation
Ouyang, W., & O’Garra, A. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.020 · Cited by 1,072
Natural killer cells and other innate lymphoid cells in cancer
Chiossone, L., Dumas, P.-Y., Vienne, M., & Vivier, E. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0061-z · Cited by 1,007
Commensal Microbiota Promote Lung Cancer Development via γδ T Cells
Jin, C., Lagoudas, G. K., Zhao, C., Bullman, S., Bhutkar, A., Hu, B., Ameh, S., Sandel, D., Liang, X. S., Mazzilli, S., et al. (2019) · Cell · doi:10.1016/j.cell.2018.12.040 · Cited by 964
Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis
Klose, C. S. N., & Artis, D. (2016) · Nature Immunology · doi:10.1038/ni.3489 · Cited by 951
Interleukin-22: Immunobiology and Pathology
Dudakov, J. A., Hanash, A. M., & van den Brink, M. R. M. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112123 · Cited by 905
“Kirchberger and colleagues identified IL-22+ cells in human colon cancer specimens and found that a model of bacteria-induced colon cancer led to accumulation of double positive IL-17+IL-22+ ILCs (366).”
BackgroundCommensal bacteria protect against food allergen sensitization
Stefka, A. T., Feehley, T., Tripathi, P., Qiu, J., McCoy, K., Mazmanian, S. K., Tjota, M. Y., Seo, G.-Y., Cao, S., Theriault, B. R., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412008111 · Cited by 795
“injection three times per week as previously described (37, 38).”
MethodCytokine Networks in the Pathophysiology of Inflammatory Bowel Disease
Friedrich, M., Pohin, M., & Powrie, F. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.017 · Cited by 750
“However, reparative effects on IEC can render IL-22 a pathogenic player in intestinal tumorigenesis if uncontrolled (Huber et al., 2012; Kirchberger et al., 2013), which may eventually limit its clinical utility.”
BackgroundIL-6 and related cytokines as the critical lynchpins between inflammation and cancer
Taniguchi, K., & Karin, M. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.001 · Cited by 716
De Simone, V, Franzè, E., Ronchetti, G., Colantoni, A., Fantini, M. C., Di Fusco, D., Sica, G. S., Sileri, P., MacDonald, T. T., Pallone, F., et al. (2015) · Oncogene · doi:10.1038/onc.2014.286 · Cited by 595
Genetic and biological hallmarks of colorectal cancer
Li, J., Ma, X., Chakravarti, D., Shalapour, S., & DePinho, R. A. (2021) · Genes & Development · doi:10.1101/gad.348226.120 · Cited by 573
“IL-22 selectively acts on epithelial cells to induce STAT3 phosphorylation and proliferation (Kirchberger et al. 2013; Loyon et al. 2019; Wang et al. 2020).”
BackgroundInnate Immune Recognition of Cancer
Woo, S.-R., Corrales, L., & Gajewski, T. F. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112043 · Cited by 571
Therapeutic opportunities of the IL-22–IL-22R1 system
Sabat, R., Ouyang, W., & Wolk, K. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4176 · Cited by 562
Innate lymphoid cells in the initiation, regulation and resolution of inflammation
Sonnenberg, G. F., & Artis, D. (2015) · Nature Medicine · doi:10.1038/nm.3892 · Cited by 503
“…numbers and cytokine production have also been observed in individuals with chronic inflammatory diseases, including in the skin of patients with psoriasis 75,122 , in tumors of patients with colitis-associated colon cancer 123 , or in the bronchoalveolar lavage fluid of patients with asthma 124 .”
Inflammatory networks underlying colorectal cancer
Lasry, A., Zinger, A., & Ben-Neriah, Y. (2016) · Nature Immunology · doi:10.1038/ni.3384 · Cited by 489
The role of IL-22 in intestinal health and disease
Keir, M. E., Yi, T., Lu, T. T., & Ghilardi, N. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20192195 · Cited by 464
“Finally, blockade of IL-22 reduced the growth of human tumor samples upon transfer into immunedeficient mice (Kryczek et al., 2014).”
BackgroundHost–microbiota maladaptation in colorectal cancer
Janney, A., Powrie, F., & Mann, E. H. (2020) · Nature · doi:10.1038/s41586-020-2729-3 · Cited by 445
Self-citationThe IL-20 subfamily of cytokines — from host defence to tissue homeostasis
Rutz, S., Wang, X., & Ouyang, W. (2014) · Nature Reviews Immunology · doi:10.1038/nri3766 · Cited by 416
Effect of tumor cells and tumor microenvironment on NK‐cell function
Vitale, M., Cantoni, C., Pietra, G., Mingari, M. C., & Moretta, L. (2014) · European Journal of Immunology · doi:10.1002/eji.201344272 · Cited by 412
AHR in the intestinal microenvironment: safeguarding barrier function
Stockinger, B., Shah, K., & Wincent, E. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00430-8 · Cited by 403
Emerging cytokine networks in colorectal cancer
West, N. R., McCuaig, S., Franchini, F., & Powrie, F. (2015) · Nature Reviews Immunology · doi:10.1038/nri3896 · Cited by 396
Albini, A., Bruno, A., Noonan, D. M., & Mortara, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00527 · Cited by 392
“Overall, the pro-tumor activities of ILC3s are mainly linked to the induction of chronic inflammation by secretion of IL-17 and IL-22, in particular in the gut, through their response to IL-23 (173).”
BackgroundInfluentialKryczek, I., Lin, Y., Nagarsheth, N., Peng, D., Zhao, L., Zhao, E., Vatan, L., Szeliga, W., Dou, Y., Owens, S., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.03.010 · Cited by 389
“Recent mouse studies have revealed that IL-22 cells stimulate tumor cell proliferation in a bacteria-induced colon cancer model (Kirchberger et al., 2013), and IL-22 binding protein (IL-22BP) reduces chemical carcinogen-induced colon-cancer development (Huber et al.”
BackgroundCX3CR1+ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22
Longman, R. S., Diehl, G. E., Victorio, D. A., Huh, J. R., Galan, C., Miraldi, E. R., Swaminath, A., Bonneau, R., Scherl, E. J., & Littman, D. R. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20140678 · Cited by 383
Hazenberg, M. D., & Spits, H. (2014) · Blood · doi:10.1182/blood-2013-11-427781 · Cited by 374
“Using an established mouse model of microbe-induced inflammatory bowel disease–associated CRC, it was found that IL-22–producing ILCs drove the induction and maintenance of CRC.(89) Thus, CRC did not develop in mice that were depleted of IL22–producing ILC3, and treatment with IL-22–blocking agents did protect against…”
BackgroundInfluentialRegulation of Obesity-Related Insulin Resistance with Gut Anti-inflammatory Agents
Luck, H., Tsai, S., Chung, J., Clemente-Casares, X., Ghazarian, M., Revelo, X. S., Lei, H., Luk, C. T., Shi, S. Y., Surendra, A., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.03.001 · Cited by 368
Innate lymphoid cells: major players in inflammatory diseases
Ebbo, M., Crinier, A., Vély, F., & Vivier, E. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.86 · Cited by 363
Innate Lymphoid Cells in Inflammation and Immunity
McKenzie, A. N. J., Spits, H., & Eberl, G. (2014) · Immunity · doi:10.1016/j.immuni.2014.09.006 · Cited by 368
Regulatory Innate Lymphoid Cells Control Innate Intestinal Inflammation
Wang, S., Xia, P., Chen, Y., Qu, Y., Xiong, Z., Ye, B., Du, Y., Tian, Y., Yin, Z., Xu, Z., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.027 · Cited by 361
“For example, ILCs are implicated in many inflammatory disorders, including inflammatory bowel diseases, allergic asthma, tissue fibrosis, and oncogenesis (Buonocore et al., 2010; Chang et al., 2011; Kirchberger et al., 2013; McHedlidze et al., 2013).”
Host-Protozoan Interactions Protect from Mucosal Infections through Activation of the Inflammasome
Chudnovskiy, A., Mortha, A., Kana, V., Kennard, A., Ramirez, J. D., Rahman, A., Remark, R., Mogno, I., Ng, R., Gnjatic, S., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.076 · Cited by 325
Exploring immunotherapy in colorectal cancer
Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01294-4 · Cited by 355
ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity
Moral, J. A., Leung, J., Rojas, L. A., Ruan, J., Zhao, J., Sethna, Z., Ramnarain, A., Gasmi, B., Gururajan, M., Redmond, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2015-4 · Cited by 348
Hayakawa, Y., Ariyama, H., Stancikova, J., Sakitani, K., Asfaha, S., Renz, B. W., Dubeykovskaya, Z. A., Shibata, W., Wang, H., Westphalen, C. B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.003 · Cited by 328
“The function of ILCs has been highlighted in the setting of inflammatory or infectious states, although the possibility has been raised of a role for ILCs in stem cell niche or cancer development (Bando et al., 2015; Hanash et al., 2012; Kirchberger et al., 2013).”
BackgroundCytokine Tuning of Intestinal Epithelial Function
Andrews, C., McLean, M. H., & Durum, S. K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01270 · Cited by 319
“Multiple studies have also shown that IL-22 alone can promote colorectal cancer progression (58, 59).”
BackgroundModulation of immune development and function by intestinal microbiota
Kabat, A. M., Srinivasan, N., & Maloy, K. J. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.07.010 · Cited by 314
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
Plasticity of innate lymphoid cell subsets
Bal, S. M., Golebski, K., & Spits, H. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0282-9 · Cited by 304
Targeting IL-10 Family Cytokines for the Treatment of Human Diseases
Wang, X., Wong, K., Ouyang, W., & Rutz, S. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028548 · Cited by 302
“Increased colon tumorigenesis is observed when IL-22 is elevated in mice with colitis undergoing carcinogen treatment (Kirchberger et al. 2013) or in mice bearing a genetic alteration (Apc) that causes colorectal cancer (Huber et al.”
BackgroundThe Role of the Microbiota in Inflammation, Carcinogenesis, and Cancer Therapy
Dzutsev, A., Goldszmid, R. S., Viaud, S., Zitvogel, L., & Trinchieri, G. (2015) · European Journal of Immunology · doi:10.1002/eji.201444972 · Cited by 300
Dzutsev, A., Badger, J. H., Perez-Chanona, E., Roy, S., Salcedo, R., Smith, C. K., & Trinchieri, G. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052133 · Cited by 302
“IL-22 is produced by T cells and innate lymphoid cells in the intestinal lamina propria and, through activation of STAT3, induces epithelial cell proliferation and production of antibacterial peptides (155).”
BackgroundGaudino, S. J., & Kumar, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00360 · Cited by 298
“ILC3s have been shown to be a major source of IL-22 in mice for promoting tumorigenesis; however, human studies indicate that CCR6 Th17 cells are major producers of IL-22 (179, 181).”
BackgroundAdipose-resident group 1 innate lymphoid cells promote obesity-associated insulin resistance
O’Sullivan, T. E., Rapp, M., Fan, X., Weizman, O.-E., Bhardwaj, P., Adams, N. M., Walzer, T., Dannenberg, A. J., & Sun, J. C. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.016 · Cited by 293
“However, persistent inflammatory signals can also lead to unrestrained activation of certain ILC populations at barrier surfaces, exacerbating colitis, dermatitis, and contributing to tumorigenesis (Buonocore et al., 2010; Chan et al., 2014; Fuchs et al., 2013; Kirchberger et al., 2013; Salimi et al., 2013).”
BackgroundRegulation and plasticity of intestinal stem cells during homeostasis and regeneration
Beumer, J., & Clevers, H. (2016) · Development · doi:10.1242/dev.133132 · Cited by 287
“Pro-inflammatory signals such as IL22 can also contribute to carcinogenesis (Kirchberger et al., 2013) and are effectively counteracted by sequestering proteins such as IL22 binding protein (IL-22BP) (Huber et al., 2012).”
BackgroundProstaglandin‐cytokine crosstalk in chronic inflammation
Yao, C., & Narumiya, S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14530 · Cited by 283
“These results have thus provided newmechanistic interpretation for epidemiological findings showing that NSAIDs prevented colorectal cancer development and progression (Thun et al., 1991; Rothwell et al., 2010) and experimental work showing that genetic deletion of COX-2, mPGES1 or EP2 receptors reduced the number and…”
BackgroundInfluentialThe role of cytokines in the regulation of NK cells in the tumor environment
Konjević, G. M., Vuletić, A. M., Mirjačić Martinović, K. M., Larsen, A. K., & Jurišić, V. B. (2019) · Cytokine · doi:10.1016/j.cyto.2019.02.001 · Cited by 279
IBD immunopathogenesis: A comprehensive review of inflammatory molecules
Park, J. H., Peyrin-Biroulet, L., Eisenhut, M., & Shin, J. I. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.02.013 · Cited by 276
“Nevertheless, in recent studies, IECs of IBD patients were found susceptible to developing a colitis-associated colorectal cancer wherein inflammatory cytokines are also considered to promote tumour cell proliferation and survival via STAT3 and NF B signaling [54, 55].”
BackgroundInfluentialInnate Lymphoid Cells in Mucosal Immunity
Panda, S. K., & Colonna, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00861 · Cited by 275
“Indeed, the key activator of ILC3s, IL-23, and the ILC3 effector cytokines IL-17 and IL-22 are associated with both experimental and clinical tumorigenesis ( Figure 1 ) (139–142).”
Cytokines, IBD, and Colitis-associated Cancer
Francescone, R., Hou, V., & Grivennikov, S. I. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000236 · Cited by 272
NCR+ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures
Carrega, P., Loiacono, F., Di Carlo, E., Scaramuccia, A., Mora, M., Conte, R., Benelli, R., Spaggiari, G. M., Cantoni, C., Campana, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9280 · Cited by 271
Functional interactions between innate lymphoid cells and adaptive immunity
Sonnenberg, G. F., & Hepworth, M. R. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0194-8 · Cited by 270
Microbiome, inflammation and colorectal cancer
Chen, J., Pitmon, E., & Wang, K. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.006 · Cited by 265
Hasnain, S. Z., Borg, D. J., Harcourt, B. E., Tong, H., Sheng, Y. H., Ng, C. P., Das, I., Wang, R., Chen, A. C.-H., Loudovaris, T., et al. (2014) · Nature Medicine · doi:10.1038/nm.3705 · Cited by 263
Peña-Romero, A. C., & Orenes-Piñero, E. (2022) · Cancers · doi:10.3390/cancers14071681 · Cited by 257
Complementarity and redundancy of IL-22-producing innate lymphoid cells
Rankin, L. C., Girard-Madoux, M. J. H., Seillet, C., Mielke, L. A., Kerdiles, Y., Fenis, A., Wieduwild, E., Putoczki, T., Mondot, S., Lantz, O., et al. (2016) · Nature Immunology · doi:10.1038/ni.3332 · Cited by 249
“NCR − ILC3 can promote colitis in a model of inflammatory bowel disease 12 .”
NF-κB pathways in the development and progression of colorectal cancer
Patel, M., Horgan, P. G., McMillan, D. C., & Edwards, J. (2018) · Translational Research · doi:10.1016/j.trsl.2018.02.002 · Cited by 250
Microbiota-mediated inflammation and antimicrobial defense in the intestine
Caballero, S., & Pamer, E. G. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120238 · Cited by 238
“IL-23 induces expression of IL22 by innate lymphocytes, which plays an important role in promoting epithelial cell proliferation when the epithelium is damaged but can also enhance tumor growth (216, 217) (Figure 2).”
Targeting JAK kinase in solid tumors: emerging opportunities and challenges
Buchert, M., Burns, C. J., & Ernst, M. (2016) · Oncogene · doi:10.1038/onc.2015.150 · Cited by 243
ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation
Pearson, C., Thornton, E. E., McKenzie, B., Schaupp, A.-L., Huskens, N., Griseri, T., West, N., Tung, S., Seddon, B. P., Uhlig, H. H., et al. (2016) · eLife · doi:10.7554/elife.10066 · Cited by 233
“Consistent with this, IL-22 alone was required for the maintenance of bacteria driven innate colitis-associated cancer (Kirchberger et al., 2013).”
BackgroundThe neuropeptide VIP confers anticipatory mucosal immunity by regulating ILC3 activity
Seillet, C., Luong, K., Tellier, J., Jacquelot, N., Shen, R. D., Hickey, P., Wimmer, V. C., Whitehead, L., Rogers, K., Smyth, G. K., et al. (2020) · Nature Immunology · doi:10.1038/s41590-019-0567-y · Cited by 234
Bhat, A. A., Nisar, S., Singh, M., Ashraf, B., Masoodi, T., Prasad, C. P., Sharma, A., Maacha, S., Karedath, T., Hashem, S., et al. (2022) · Cancer Communications · doi:10.1002/cac2.12295 · Cited by 229
IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs
Barone, F., Nayar, S., Campos, J., Cloake, T., Withers, D. R., Toellner, K.-M., Zhang, Y., Fouser, L., Fisher, B., Bowman, S., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1503315112 · Cited by 229
“Recently, Il-22 has been implicated in malignant epithelial cell proliferation (23), but its role in chronic inflammation remains enigmatic (15).”
BackgroundLiao, Y., Zhao, J., Bulek, K., Tang, F., Chen, X., Cai, G., Jia, S., Fox, P. L., Huang, E., Pizarro, T. T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14698-y · Cited by 227
Mjösberg, J., & Spits, H. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.09.009 · Cited by 222
Helminth therapy or elimination: epidemiological, immunological, and clinical considerations
Wammes, L. J., Mpairwe, H., Elliott, A. M., & Yazdanbakhsh, M. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70771-6 · Cited by 218
Human immunology and immunotherapy: main achievements and challenges
Varadé, J., Magadán, S., & González-Fernández, Á. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00530-6 · Cited by 216
Cytokine-Induced Modulation of Colorectal Cancer
Mager, L. F., Wasmer, M.-H., Rau, T. T., & Krebs, P. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00096 · Cited by 216
“In Helicobacter hepaticus/AOM-induced intestinal tumors, IL-22 released by ILCs supported the growth of intestinal tumors in T and B cell-deficient Rag2−/− mice (138).”
BackgroundDysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer
Goc, J., Lv, M., Bessman, N. J., Flamar, A.-L., Sahota, S., Suzuki, H., Teng, F., Putzel, G. G., Eberl, G., Withers, D. R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.029 · Cited by 212
IL-10 and IL-22 in Mucosal Immunity: Driving Protection and Pathology
Wei, H.-X., Wang, B., & Li, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01315 · Cited by 209
“These ILCs produce IL-22 that promotes cancer development by inducing epithelial cell proliferation through phosphorylation of the Stat3 pathway; neutralization of IL-22 leads to abrogation of this process (140).”
BackgroundInteractions between innate and adaptive lymphocytes
Gasteiger, G., & Rudensky, A. Y. (2014) · Nature Reviews Immunology · doi:10.1038/nri3726 · Cited by 208
Cell plasticity in epithelial homeostasis and tumorigenesis
Varga, J., & Greten, F. R. (2017) · Nature Cell Biology · doi:10.1038/ncb3611 · Cited by 204
Gata3 drives development of RORγt+ group 3 innate lymphoid cells
Serafini, N., Klein Wolterink, R. G. J., Satoh-Takayama, N., Xu, W., Vosshenrich, C. A. J., Hendriks, R. W., & Di Santo, J. P. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131038 · Cited by 203
“Lastly, a heterogeneous population of NKp46 CD4 ILC3 exists that has been implicated in intestinal inflammation and colonic tumor formation (Buonocore et al., 2010; Kirchberger et al., 2013).”
Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC
Hu, C., Xu, B., Wang, X., Wan, W., Lu, J., Kong, D., Jin, Y., You, W., Sun, H., Mu, X., et al. (2023) · Hepatology · doi:10.1002/hep.32449 · Cited by 199
“In colorectal cancer, ILC3‐derived IL‐22 induces abnormal epithelial cell proliferation.[7] However, the role of ILC3s in liver cancer is still unclear.”
BackgroundGeis, A. L., Fan, H., Wu, X., Wu, S., Huso, D. L., Wolfe, J. L., Sears, C. L., Pardoll, D. M., & Housseau, F. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0447 · Cited by 195
“Multiple murine models of immunemediated carcinogenesis establish the IL-17 response as critical, particularly in the intestine (6-9).”
Group 3 innate lymphoid cells (ILC3s): Origin, differentiation, and plasticity in humans and mice
Montaldo, E., Juelke, K., & Romagnani, C. (2015) · European Journal of Immunology · doi:10.1002/eji.201545598 · Cited by 190
Dmitrieva-Posocco, O., Dzutsev, A., Posocco, D. F., Hou, V., Yuan, W., Thovarai, V., Mufazalov, I. A., Gunzer, M., Shilovskiy, I. P., Khaitov, M. R., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.11.015 · Cited by 188
Innate lymphoid cells and cancer
Jacquelot, N., Seillet, C., Vivier, E., & Belz, G. T. (2022) · Nature Immunology · doi:10.1038/s41590-022-01127-z · Cited by 185
Geng, H., Bu, H.-F., Liu, F., Wu, L., Pfeifer, K., Chou, P. M., Wang, X., Sun, J., Lu, L., Pandey, A., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.03.058 · Cited by 182
Inflammation and Colorectal Cancer
Long, A. G., Lundsmith, E. T., & Hamilton, K. E. (2017) · Current Colorectal Cancer Reports · doi:10.1007/s11888-017-0373-6 · Cited by 174
The Role of Interleukin 17 in Tumour Proliferation, Angiogenesis, and Metastasis
Yang, B., Kang, H., Fung, A., Zhao, H., Wang, T., & Ma, D. (2014) · Mediators of Inflammation · doi:10.1155/2014/623759 · Cited by 169
“Results show that, despite the strong link between IL-17 and inflammatory bowel disease, there is no significant increase in IL-17 levels in patients with colorectal carcinomas [127, 128].”
BackgroundTranslating Immunology into Therapeutic Concepts for Inflammatory Bowel Disease
Uhlig, H. H., & Powrie, F. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053055 · Cited by 169
Jones, G. W., Hill, D. G., & Jones, S. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00401 · Cited by 169
The Fire Within: Microbes Inflame Tumors
Gagliani, N., Hu, B., Huber, S., Elinav, E., & Flavell, R. A. (2014) · Cell · doi:10.1016/j.cell.2014.03.006 · Cited by 165
“On the other hand, bacterial components can also stimulate DC to produce IL-23 (Kinnebrew et al., 2012), which induces IL-22 production by ILC3 (Huber et al., 2012a; Kirchberger et al., 2013).”
BackgroundInfluentialThe role of the IL-22/IL-22R1 axis in cancer
Lim, C., & Savan, R. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.04.005 · Cited by 163
“necessary for the transition from colitis to colorectal cancer by increasing inflammation and proliferation; neutralization of IL-22 rescued tumor progression more effectively than that of IL-17 [79].”
BackgroundInfluentialTumor-Elicited Inflammation and Colorectal Cancer
(2015) · Advances in Cancer Research · doi:10.1016/bs.acr.2015.04.014 · Cited by 161
IL-21 induces IL-22 production in CD4+ T cells
Yeste, A., Mascanfroni, I. D., Nadeau, M., Burns, E. J., Tukpah, A.-M., Santiago, A., Wu, C., Patel, B., Kumar, D., & Quintana, F. J. (2014) · Nature Communications · doi:10.1038/ncomms4753 · Cited by 159
Zhu, Y., Shi, T., Lu, X., Xu, Z., Qu, J., Zhang, Z., Shi, G., Shen, S., Hou, Y., Chen, Y., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020105320 · Cited by 151
Innate Lymphoid Cells in Intestinal Inflammation
Geremia, A., & Arancibia-Cárcamo, C. V. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01296 · Cited by 154
“hepaticus long-term or co-treated with 2-azoxymethane (a cancer inducing agent) (101).”
BackgroundPlasticity within stem cell hierarchies in mammalian epithelia
Tetteh, P. W., Farin, H. F., & Clevers, H. C. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.09.003 · Cited by 176
“In this section, we discuss emerging concepts from recent literature that employ genetic lineage tracing in mice to show how stem cell hierarchies and plasticity are realized in other mammalian epithelial tissues during homeostasis and regeneration.”
Mokarram, P., Albokashy, M., Zarghooni, M., Moosavi, M. A., Sepehri, Z., Chen, Q. M., Hudecki, A., Sargazi, A., Alizadeh, J., Moghadam, A. R., et al. (2017) · Autophagy · doi:10.1080/15548627.2017.1290751 · Cited by 159
“Furthermore, colonic innate lymphoid cells (ILCs) play a pivotal role in microbiome-influenced CRC via regulation of IL23A-dependent on IL22 secretion, which is mediated by inducing phosphorylation of STAT3 in a mouse model.(119) Autophagy is activated in the intestinal epithelium of CRC patients and a mouse model of…”
BackgroundTGF-β signaling in Th17 cells promotes IL-22 production and colitis-associated colon cancer
Pérez, L. G., Kempski, J., McGee, H. M., Pelczar, P., Agalioti, T., Giannou, A. D., Konczalla, L., Brockmann, L., Wahib, R., Xu, H. Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16363-w · Cited by 172
IL-22 Mediates Goblet Cell Hyperplasia and Worm Expulsion in Intestinal Helminth Infection
Turner, J.-E., Stockinger, B., & Helmby, H. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003698 · Cited by 145
“In addition, IL-22 has also been shown to play a detrimental role in chronic mucosal inflammation and progression to colorectal cancer [32,33] demonstrating a pivotal role for IL-22 in balancing tissue regeneration and tumour development in the intestinal environment.”
BackgroundNLRC4 expression in intestinal epithelial cells mediates protection against an enteric pathogen
Nordlander, S., Pott, J., & Maloy, K. J. (2014) · Mucosal Immunology · doi:10.1038/mi.2013.95 · Cited by 145
“36 When assayed for NLRC4 expression, we found that IEC crypts in both cecum and colon had the highest levels of NLRC4, significantly greater than the levels expressed by LPLs (Fig.5F).”
Powell, N., Pantazi, E. D., Pavlidis, P., Tsakmaki, A., Li, K., Yang, F., Parker, A., Pin, C., Cozzetto, D., Minns, D., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318483 · Cited by 145
Brockmann, L., Giannou, A., Gagliani, N., & Huber, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051033 · Cited by 144
Chan, I. H., JAIN, R. K., Tessmer, M. S., Gorman, D., Mangadu, R., Sathe, M., Vives, F., Moon, C., Penaflor, E., Turner, S. P., et al. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.101 · Cited by 149
“These results imply that neither the IL-17induced downstream cytokines nor the IL-22 attributed cytoprotective and proliferative phenotypes were sufficient for initiating adenoma development, although IL-22 expression in ILC has recently been demonstrated to have a critical role for maintenance and progression of Heli…”
ResultBiological and pathological activities of interleukin-22
Perusina Lanfranca, M., Lin, Y., Fang, J., Zou, W., & Frankel, T. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1391-6 · Cited by 141
Metadata
- Authors
- Kirchberger, S., Royston, D. J., Boulard, O., Thornton, E., Franchini, F., Szabady, R. L., Harrison, O., & Powrie, F.
- Affiliations
- John Radcliffe Hospital (GB)
- University of Oxford (GB)
- Corresponding author
- Powrie, Fiona
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2013-04-15
- Volume
- 210
- Issue
- 5
- Pages
- 917-931
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3646494
- OpenAlex
- W2124499950
- Cited by
- 529
- References
- 52
- Citations by year
- 2026: 18 · 2025: 12 · 2024: 24 · 2023: 33 · 2022: 39 · 2021: 34 · 2020: 54 · 2019: 51 · 2018: 42 · 2017: 55 · 2016: 48 · 2015: 54 · 2014: 50 · 2013: 12
- FWCI
- 30.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
- Funders
- Royal College of Pathologists of Australasia
- Wellcome Trust (095688/Z/11/Z, 095688)
- Cancer Research UK (A7297, A11663)
- National Institute for Health and Care Research
- European Commission (223151)
- Jean Shanks Foundation
- Austrian Science Fund
- Genentech
- Biotechnology and Biological Sciences Research Council (BB/I005609/1)
- NIHR Oxford Biomedical Research Centre
- UCB Celltech
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- colon cancer, IL-22, IL-17, innate lymphoid cells, inflammatory bowel disease, STAT3 phosphorylation, epithelial cell proliferation, therapeutic target
- MeSH terms
- Interleukin-22, Animals, Antigens, Ly, Cell Transformation, Neoplastic, Colitis, Colon, Colonic Neoplasms, Disease Models, Animal, Epithelial Cells, Humans, Interleukins, Lymphocytes, Phosphorylation, CD4 Antigens, Gene Expression Regulation, Neoplastic, Helicobacter, Disease Progression, Cell Lineage, STAT3 Transcription Factor, Mice, Natural Cytotoxicity Triggering Receptor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.